MorphoSys AG clinical trials
Acquired by Novartis, May 23, 2024 · source ↗
The registry lists 11 studies whose lead sponsor is MorphoSys AG. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 16, 2024.
- 11studies on the registry
- 0open to participants now
Before and after it joined Novartis
- First submitted before MorphoSys AG became part of Novartis
- 11
- First submitted after MorphoSys AG became part of Novartis
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs MorphoSys AG’s studies test, most studies first; none is open now — 3 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 11 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 09
- 10
- 11
- 12
- 213
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- MorphoSys AG11 studies
Something wrong with this grouping? Tell us on the Novartis page.
Studies
Recruiting first, then most recently updated. Showing 11 of 11. All Novartis studies →
- Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCLCompletedNCT04134936Phase 1
Sponsor listed in the registry: MorphoSys AG · First submitted before MorphoSys AG became part of Novartis
- Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)CompletedNCT01685008Phase 2
Sponsor listed in the registry: MorphoSys AG · First submitted before MorphoSys AG became part of Novartis
- Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCLCompletedNCT02399085Phase 2
Sponsor listed in the registry: MorphoSys AG · First submitted before MorphoSys AG became part of Novartis
- Lenalidomide Monotherapy in R/R DLBCLCompletedNCT04150328
Sponsor listed in the registry: MorphoSys AG · First submitted before MorphoSys AG became part of Novartis
- Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKiCompletedNCT02639910Phase 2
Sponsor listed in the registry: MorphoSys AG · First submitted before MorphoSys AG became part of Novartis
- A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple MyelomaCompletedNCT01421186Phase 1/2
Sponsor listed in the registry: MorphoSys AG · First submitted before MorphoSys AG became part of Novartis
- Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCLCompletedNCT04697160
Sponsor listed in the registry: MorphoSys AG · First submitted before MorphoSys AG became part of Novartis
- Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCLApproved for marketingNCT04300803
Sponsor listed in the registry: MorphoSys AG · First submitted before MorphoSys AG became part of Novartis
- Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)TerminatedNCT01685021Phase 2
Sponsor listed in the registry: MorphoSys AG · First submitted before MorphoSys AG became part of Novartis
- Phase Ib Study to Evaluate MOR103 in Multiple SclerosisCompletedNCT01517282Phase 1/2
Sponsor listed in the registry: MorphoSys AG · First submitted before MorphoSys AG became part of Novartis
- Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid ArthritisCompletedNCT01023256Phase 1/2
Sponsor listed in the registry: MorphoSys AG · First submitted before MorphoSys AG became part of Novartis